Navigation Links
Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
Date:11/7/2013

ase Oprozomib Tablets in Patients (Pts) With Hematologic Malignancies: Updated Results From a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

  • Dr. Irene M. Ghobrial, Dana-Farber Cancer Institute
  • Sunday, December 8, 6:30 pm - 8:30 pm CT, Hall G
  • Poster presentation: Myeloma: Therapy, excluding Transplantation: Poster II
  • Abstract # 3184

Select Investigator-Sponsored carfilzomib abstracts:

Dose Escalation Phase 2 Trial Of Carfilzomib Combined With Thalidomide and Low-Dose Dexamethasone In Newly Diagnosed, Transplant Eligible Patients With Multiple Myeloma. A Trial Of The European Myeloma Network

  • Dr. Pieter Sonneveld, Erasmus Medical Center, Rotterdam, Netherlands
  • Monday, December 9, 5:15 pm CT, 393-394
  • Oral Presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 688

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma

  • Dr. Sara Bringhen, Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
  • Monday, December 9, 4:30 pm CT, 393-394
  • Oral presentation: Myeloma: Therapy, excluding Transplantation II
  • Abstract # 685

A simple score, based on geriatric assessment, improves prediction of survival, and risk of serious adverse events in elderly newly diagnosed multiple myeloma patients

  • Dr. Alessandra Larocca, Myeloma Unit, Division of Hematology, University of Torino, Torino, Italy
  • M
    '/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , September 30, 2014 ... intuitive browsing of chemistry in documents ... software solutions and consulting services for life science ... information and generate Markush structures from documents. ... organizations intellectual property, however generating and understanding Markush ...
(Date:9/30/2014)... Sept. 30, 2014 FemCap Inc., www.femcap.com ... its receipt of a patent No: US, 8,795,248 B2 ... also received FDA clearance in the U.S., 510(K) K121857, ... in Europe. This patent is related to its menstrual cup ... the company is releasing FemmyCycle Teen, a third menstrual ...
(Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
(Date:9/30/2014)... Back in the 1970’s, many companies calculated their ... which included space for circulation and file storage. “It ... at Nidea Corporate Real Estate / ITRA Global , ... 2000, however, 250 square feet per employee became the ... to 175 to 225 square feet, and over the next ...
Breaking Biology Technology:ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3
... , ... , , , Antibodies ... arrays) or as biopharmaceutical therapeutics. In,all cases the successful production ... criteria include: protein identification,quantitation and the monitoring of purity and ...
... , ... , , , ... of the Agilent 2100 bioanalyzer in combination,with the Protein 200 Plus ... denaturing gel-elctrophoresis (SDSPAGE).,The results showed that the Agilent 2100 bioanalyzer provides,fast ...
... , ... , , , , ... an siRNA sequence,for a target gene, which are of,high importance ... crucial.,An efficient method to optimize,transfection and gene silencing,is critical for ...
Cached Biology Technology:Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 2Quality control of antibodies using the,2100 bioanalyzer and the Protein 200,Plus assay 3Comparison of different protein,quantitation methods 2Comparison of different protein,quantitation methods 3Comparison of different protein,quantitation methods 4Comparison of different protein,quantitation methods 5Comparison of different protein,quantitation methods 6Comparison of different protein,quantitation methods 7Comparison of different protein,quantitation methods 8Comparison of different protein,quantitation methods 9Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 2Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 3Confirming gene silencing,mechanism by pGFP/GFP22 ,siRNA co-transfection 4
(Date:9/30/2014)... Salk professor and Howard Hughes Medical Institute investigator, ... named recipients in the 2014 round of grants ... the BRAIN (Brain Research through Advancing Innovative Neurotechnologies) ... announced September 30, provides more than $3 million ... years. , The BRAIN Initiative, launched last year, ...
(Date:9/30/2014)... water may increase the risk of stillbirth and ... by a Boston University School of Public Health ... Environmental Health , compared 1,091 PCE-exposed pregnancies ... Cape Cod, Ma., where water was contaminated in ... the installation of vinyl-lined asbestos cement pipes. PCE ...
(Date:9/30/2014)... live in almost any aquatic environment on Earth, but ... species are pushed to the limit. The amount of ... critical for how different species cope in the future, ... of Gothenburg, published in the scientific journal Proceedings ... continues apace thanks to increasing levels of greenhouse gases ...
Breaking Biology News(10 mins):Salk scientists receive $3 million for BRAIN Initiative grant 2Contaminated water linked to pregnancy complications, BU study finds 2Shape up quickly -- applies to fish, too! 2
... in ecological or environmental conservation remains contentious the ... demand that governments regulate and encourage restoration projects; ... corporations makes such interventions politically difficult. However, ... a handful of developing nations, alongside South Africa, ...
... , RIVERSIDE, Calif. Alan McHughen , a ... University of California, Riverside, has been chosen by the ... Sciences to receive a 2011-2012 Jefferson Science Fellowship ... selected for the fellowships this year. Successful ...
... is redefining the rules by which we live and at ... level, several areas of the globe are in danger of ... and maybe, one day, live in floating houses. Depending ... others in their adjustment to the effects of global warming, ...
Cached Biology News:UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship 2UC Riverside plant biotechnologist receives prestigious Jefferson Science Fellowship 3Floating houses 2Floating houses 3